BiotechTV - News
tekijä: BiotechTV
Uusin jakso
STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS…
STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS…
Tietoa podcastista
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Jaksot
Uusimmat 50 jaksoa 510 jaksosta
- STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors · 8 minCo-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of…
- STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month · 11 minCEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December…
- Stifel's Tim Opler on the state of biotech · 10 minAhead of a 100+ slide "State of Biotech" report he is publishing tomorrow, he discusses the impact of Washington on biotech, how the sector has been trading lately, China, M&A…
- STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months · 19 minCEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen…
- STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1 · 9 minCo-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and…
- STIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead · 8 minHe describes the company's precision mechanism, and discussions they will have with FDA before starting phase 3 trials in this indicuation next year. Plus, previewing long-term…
- Stifel's Head of Global Equity Capital Markets Seth Rubin shares his take on the state of biotech and the current environment for companies to raise money · 5 minHe says that markets have taken a pause but he believes they are healthy and not broken, and he is optimistic about the future.
- STIFEL 2026: REGENXBIO will have its pivotal studies for wet AMD read out before the end of the year - combined, they are the largest study of a gene therapy ever · 8 minCEO Curran Simpson sets the table for the readouts and describes what he believes they need to show in order to succeed. Plus, updates on the DMD program and RGX-121.
- STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific · 11 minCEO Eran Ophir defines what would be a success in the ovarian trial and possible next steps if successful. Plus, TIGIT, Gilead's work on IL18, and looking for new T-cell engager…
- STIFEL 2026: Cullinan Therapeutics' CEO Nadim Ahmed gives an overview of the progress of the company's T-cell engagers in autoimmune and oncology (and more) · 11 minHe goes over a partner's BCMA data that was just presented this weekend at ACR in lupus, and previews a key CD19 update that Cullinan will be providing investors in December…
- Stifel Research Analyst Alex Thompson shares his take on the state of the I&I space and highlights a few key companies · 9 minHe discusses Kymera, Roivant, and Oruka.
- STIFEL 2026: Over the last two week, Marengo Therapeutics has published landmark data on its Vβ-directed platforms in Nature Medicine, and presented new clinical data in breast cancer at SITC · 10 minCEO Zhen Su describes the platform and walks us through the SITC data, which was given on top of Trodelvy.
- STIFEL 2026: Alkermes' new CEO Blair Jackson describes his priorities for the company - which include a heavy focus on the emerging orexin agonist class · 11 minHe describes the profile of the company's orexin and its development path (a key trial in Idiopathic Hypersomnia will be reading out soon), which also includes indications like…
- STIFEL 2026: Korsana Biosciences is using a proprietary brain shuttle and a beta amyloid targeting therapy and aims to take Alzheimer's treatment to the next level · 9 minPresident and CEO Jonathan Violin compares and contrasts his product with other brain shuttles and discusses the road ahead. They will present preclinical data at CTAD next week…
- Stifel's Head of Therapeutics Research Paul Matteis shares his take on biotech and discusses companies he covers that have been in the news · 13 minHe discusses Biogen, Alnylam, Xenon, and Compass Pathways
- From Montreal: Congruence Therapeutics uses computational discovery to develop novel small molecule correctors and allosteric modulators - its lead program is for a high profile genetic obesity target · 10 minFounder & CEO Clarissa Desjardins describes Congruence's Revenir product engine and walks us through programs that include MC4R deficient obesity, which is in the clinic, alpha-1…
- Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B · 15 minCEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their…
- From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada · 20 minSofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what…
- Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC · 11 minCEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after…
- After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond) · 21 minPresident and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses…
- At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2 · 23 minCEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.
- London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system · 14 minCEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system…
- Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1 · 12 minCEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
- At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research · 20 minThey discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical…
- Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more · 24 minFrom the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in…
- After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress · 27 minHe describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus…
- Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease · 21 minCEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.
- From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung · 8 minCEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and…
- From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage · 9 minCo-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.
- From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections · 14 minCEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most…
- Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study · 10 minChris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to…
- HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs · 15 minShe highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's…
- HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA · 11 minCEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.
- HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology · 9 minHe discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.
- HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune · 9 minFounder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is…
- HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic." · 9 minPascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by…
- HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9 · 8 minCo-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which…
- HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader · 10 minCEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of…
- HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications · 9 minCEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease…
- HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while · 6 minHe discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.
- HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch · 10 minBased on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on…
- HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator · 8 minOV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that…
- HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech · 7 minHe discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been…
- HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab · 8 minCEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate…
- HCW 2026: Trevi Therapeutics was founded under the premise that cough is a brain problem, not a lung problem - it seems to be playing out in the clinic · 6 minCo-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an…
- HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better · 11 minFounder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and…
- HCW 2026: Switzerland based Oculis focuses today on neuro-ophthalmology, which has led them to a pivotal trial in optic neuritis and key mid-stage data coming this year in dry eye disease · 9 minCEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry…
- Bay Area based Shennon Biotechnologies announced a new CEO today, Cyril Konto, and a $12M raise to advance its T-cell engager programs · 11 minIt also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.
- UC Berkeley's Gokul Upadhyayula and Eric Betzig are building AI to interpret detailed movies of living cells captured by their MOSAIC microscope · 21 minThe work could help guide drug discovery and development by revealing how disease disrupts cells.
- Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases · 11 minCo-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.
